We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Quantum Phar. | LSE:QP. | London | Ordinary Share | GB00BRTL8Q42 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 84.2374 | 84.00 | 84.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMQP.
RNS Number : 5135K
Quantum Pharma PLC
10 July 2017
For immediate release 10 July 2017
Quantum Pharma Plc
('Quantum' or the 'Company')
Grant of SAYE options
Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier is pleased to announce that on 7 July 2017 pursuant to the Quantum Pharma Plc Save-As-You-Earn Plan (SAYE), the Company has granted options, under which employees have been offered the opportunity to participate in the future growth of the Company via share option arrangements.
UK and Greek based employees were invited to subscribe for options over the Company's Ordinary Shares of 10 pence each ('Ordinary Shares') with an exercise price of 42.87 pence, a 20% discount to the average closing middle market price of the Company's Ordinary Shares on 9, 12 and 13 June 2017, the three trading days prior to the invitation to participate was made. The options have a contract start date of 1 September 2017 and are exercisable between 1 September 2020 and 28 February 2021.
A total of 98 employees elected to participate, and pursuant to these elections a total of 981,519 options over Ordinary Shares have been issued, equating to approximately 0.58% of the current issued share capital.
Following the above SAYE grant and other recent lapses or grants of Long Term Incentive Plan options (LTIP) or earlier SAYE grants, there are outstanding options over 16,243,928 Ordinary Shares, representing approximately 9.61% of the current issued share capital, of which options over 15,610,828 Ordinary Shares are included in the calculation of the 10% limit under the LTIP and SAYE share plan rules.
- Ends -
For further information: Quantum Pharma Plc Chris Rigg, Chief Executive Tel: +44 (0) 1207 279 404 Officer Gerard Murray, Chief Financial www.quantumpharmaplc.com Officer ir@quantumpharma.co.uk N+1 Singer (Nominated Advisor & Broker) Sandy Fraser / Nick Owen / James Tel: +44 (0) 20 7496 3000 White Media enquiries: Buchanan Sophie Cowles / Steph Watson Tel: +44 (0) 20 7466 5000 quantumpharma@buchanan.uk.com www.buchanan.uk.com
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale and hospital markets. Quantum Pharma Plc operates through two divisions - Specials and Niche Pharmaceuticals - offering a portfolio of innovative and complementary products and services.
For further information, please visit www.quantumpharmagroup.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKXXESEXEFF
(END) Dow Jones Newswires
July 10, 2017 02:00 ET (06:00 GMT)
1 Year Quantum Phar. Chart |
1 Month Quantum Phar. Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
